title: Ldl-C Lowering Efficacy of Evolocumab (Amg 145) Could Reduce Apheresis in Patients At High Risk for Cardiovascular Events in Germany.
authors.affiliation: Amgen (Europe) GmbH, Zug, Switzerland.
authors.forename: G
authors.initials: G
authors.lastname: Villa
authors.affiliation: Amgen GmbH, München, Germany.
authors.forename: T
authors.initials: T
authors.lastname: Schmid
authors.affiliation: Amgen (Europe) GmbH, Zug, Switzerland.
authors.forename: M
authors.initials: M
authors.lastname: Lothgren
authors.affiliation: Amgen GmbH, München, Germany.
authors.forename: G
authors.initials: G
authors.lastname: Michailov